China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)
NCT ID: NCT05221580
Last Updated: 2024-06-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
887 participants
OBSERVATIONAL
2022-03-18
2023-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will get Ryzodeg® as prescribed to by their doctor. The study will last for about 5-8 months. Participants will be asked questions about their health and their diabetes treatment as part of their normal doctor's appointment
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM
NCT06199505
Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes
NCT00184561
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes
NCT05834868
Phase III Insulin Add-On Asia Regional Program - ST
NCT02096705
Safety, Pharmacokinetics and Pharmacodynamics of Two IDegAsp (One Explorative) Preparations and Two Insulin Degludec (One Explorative) Preparations in Japanese Subjects
NCT01868555
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Real-world adult population of Chinese patients with T2DM
Ryzodec as per local clinical practise
Ryzodeg®
Patients will be treated with commercially available Ryzodeg® in a prefilled device (FlexTouch®) or in a penfill according to the label and routine clinical practice at the discretion of the treating physician
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ryzodeg®
Patients will be treated with commercially available Ryzodeg® in a prefilled device (FlexTouch®) or in a penfill according to the label and routine clinical practice at the discretion of the treating physician
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on the approved Ryzodeg® label in China and independently from the decision to include the patient in this study.
3. Male or female, age above or equal to 18 years at the time of signing informed consent.
4. Diagnosed with T2DM and treated with any anti-hyperglycaemic medication(s) other than Ryzodeg® for at least 20 weeks prior to Treatment Initiation Visit (Visit 1).
5. Available and documented Glycosylated haemoglobin (HbA1c) value below or equal to 12 weeks prior to Informed Consent and Treatment Initiation Visit (Visit 1).
Exclusion Criteria
2. Treatment with any investigational drug within 30 days prior to enrolment into the study.
3. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
4. Known or suspected hypersensitivity to the active substance or to any of the excipients as specified in the approved Ryzodeg® label in China.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Transparency (dept. 2834)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NIS-The Second People's Hospital of Hefei
Hefei, Anhui, China
NIS-Beijing Hospital
Beijing, Beijing Municipality, China
NIS-Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
NIS-People's Hospital of Chongqing Banan District
Chongqing, Chongqing Municipality, China
NIS-Gansu Provincial People's Hospital
Lanzhou, Gansu, China
NIS-The people's hospital of JiangMen
Jiangmen, Guangdong, China
NIS-2nd Affiliated Hospital of Shantou University Medical
Shantou, Guangdong, China
NIS-Shenzhen Longgang District People's Hospital
Shenzhen, Guangdong, China
NIS-Yangjiang People's Hospital
Yangjiang, Guangdong, China
NIS-The First People's Hospital of Yulin City
Yulin, Guangxi, China
NIS-Hainan Provincial Hospital of TCM
Haikou, Hainan, China
NIS-Cangzhou Hosp of Integrated Traditional Chinese Medicine
Cangzhou, Hebei, China
NIS-The First Hospital of Handan
Handan, Hebei, China
NIS-The First Hospital of Qinhuangdao
Qinhuangdao, Hebei, China
NIS-Heilongjiang Provincial Hospital
Harbin, Heilongjiang, China
NIS-Zhengzhou University - The Second Affiliated Hospital
Zhengzhou, Henan, China
NIS-Shiyan City People's Hospital
Shiyan, Hubei, China
NIS-Puai Hospital of Wuhan
Wuhan, Hubei, China
NIS-The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
NIS-The Sceond Hospital of Chifeng
Chifeng, Inner Mongolia, China
NIS-Inner Mongolia University for Nationalities - Affiliated
Tongliao, Inner Mongolia, China
NIS-Changshu Second People's Hospital
Changshu, Jiangsu, China
NIS-Huai'an First People's Hospital
Huai'an, Jiangsu, China
NIS-Nanjing Jiangning Hospital
Nanjing, Jiangsu, China
NIS-Jiangsu Province Officeial Hospital
Nanjing, Jiangsu, China
NIS-Nantong University - Affiliated Hospital
Nantong, Jiangsu, China
NIS-Yixing City People's Hospital
Yixing, Jiangsu, China
NIS-Affiliated Hospital of Jilin Medical College
Jilin, Jilin, China
NIS-Songyuan Jilin Oilfield Hospital
Songyuan, Jilin, China
NIS-The Third People's Hospital of Dalian
Dalian, Liaoning, China
NIS-Huludao Central Hospital
Huludao, Liaoning, China
NIS-Third Affiliated Hospital of Jinzhou Medical University
Jinzhou, Liaoning, China
NIS-The Fourth Hospital of China Medical University
Shenyang, Liaoning, China
NIS-The People's Hospital of Ningxia Hui Autonomous Region
Yinchuan, Ningxia, China
NIS- Qinghai Red Cross Hospital
Xining, Qinghai, China
NIS-Hanzhong Central Hospital
Hanzhong, Shaanxi, China
NIS-Shanxi Bethune Hospital
Taiyuan, Shaanxi, China
NIS-Xi'an No.3 Hospital
Xi'an, Shaanxi, China
NIS-Weifang Medical University - Affiliated Hospital
Weifang, Shandong, China
NIS-Binzhou Medical University-Yantai Affiliated Hospital
Yantai, Shandong, China
NIS-Central hospital of zibo
Zhibo, Shandong, China
NIS-Shanghai Shidong Hospital
Shanghai, Shanghai Municipality, China
NIS-Shanghai Shuguang Hospital
Shanghai, Shanghai Municipality, China
NIS-Affiliated Hospital of North Sichuan Medical College
Nanchong, Sichuan, China
NIS-Metabolic Diseases Hosp&Tianjin Institute of Endocrinolo
Tianjin, Tianjin Municipality, China
NIS-Tianjin First Center Hospital
Tianjin, Tianjin Municipality, China
NIS-De Hong Zhou People's Hospital
Mang City, Yunnan, China
NIS-The First People's Hospital of Qujing
Qujing, Yunnan, China
NIS-Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
NIS-Shaoxing Central Hospital
Shaoxing, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1238-6960
Identifier Type: OTHER
Identifier Source: secondary_id
NN5401-4623
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.